[go: up one dir, main page]

MX2016013151A - Nuevos derivados quinona de cannabidiol. - Google Patents

Nuevos derivados quinona de cannabidiol.

Info

Publication number
MX2016013151A
MX2016013151A MX2016013151A MX2016013151A MX2016013151A MX 2016013151 A MX2016013151 A MX 2016013151A MX 2016013151 A MX2016013151 A MX 2016013151A MX 2016013151 A MX2016013151 A MX 2016013151A MX 2016013151 A MX2016013151 A MX 2016013151A
Authority
MX
Mexico
Prior art keywords
compounds
quinone derivatives
linear
formula
branched group
Prior art date
Application number
MX2016013151A
Other languages
English (en)
Other versions
MX352386B (es
Inventor
Appendino Giovanni
Luz Bellido Cabello De Alba María
Muñoz Blanco Eduardo
Original Assignee
Vivacell Biotechnology España S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivacell Biotechnology España S L filed Critical Vivacell Biotechnology España S L
Publication of MX2016013151A publication Critical patent/MX2016013151A/es
Publication of MX352386B publication Critical patent/MX352386B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/28—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of non-condensed quinone rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/95—Esters of quinone carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a nuevos derivados quinona de cannabidiol de formula (1) en la que R es el átomo de carbono de un, grupo lineal o ramificado, representado por: grupo alquilo, arilo,alquenilo, alquinilo, acilo o alcoxicarbonilo; o en la que R es el átomo de nitrógeno de un, grupo lineal o ramificado representado por: grupos alquilamino, arilamino, alqueniolamino o alquinilamino. La invención también se refiere al uso de cualquiera de los compuestos de fórmula (1) como medicamentos en terapia, particularmente para el tratamiento de enfermedades y afecciones que responden a la modulación del PPARg debido a su alto efecto agonista del PPARg carente de actividades alectrófilas (activación del Nrf2) y citotóxicas. Esta invención también proporciona composiciones farmacéuticas que comprenden dichos compuestos y en método para el tratamiento de enfermedades con dichos compuestos.
MX2016013151A 2014-04-16 2014-04-16 Nuevos derivados quinona de cannabidiol. MX352386B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/057767 WO2015158381A1 (en) 2014-04-16 2014-04-16 Novel cannabidiol quinone derivatives

Publications (2)

Publication Number Publication Date
MX2016013151A true MX2016013151A (es) 2017-02-02
MX352386B MX352386B (es) 2017-11-22

Family

ID=50693623

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013151A MX352386B (es) 2014-04-16 2014-04-16 Nuevos derivados quinona de cannabidiol.

Country Status (14)

Country Link
US (1) US9701618B2 (es)
EP (1) EP3131874B1 (es)
JP (1) JP6167248B2 (es)
KR (1) KR102256398B1 (es)
CN (1) CN106232570B (es)
AU (1) AU2014390738B2 (es)
BR (1) BR112016023902A2 (es)
CA (1) CA2945867C (es)
DK (1) DK3131874T3 (es)
ES (1) ES2692693T3 (es)
IL (1) IL248030B (es)
MX (1) MX352386B (es)
RU (1) RU2667504C2 (es)
WO (1) WO2015158381A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL269623B2 (en) * 2017-03-29 2025-05-01 Emerald Health Pharmaceuticals Inc Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity
CN106866419B (zh) * 2017-04-14 2020-01-10 石河子大学 一类萜酯化合物及其制备方法和用途
CN111032088A (zh) * 2017-06-20 2020-04-17 耶路撒冷希伯来大学伊森姆研究发展有限公司 大麻二酚酸酯类组合物及其用途
US20220041538A1 (en) * 2018-12-11 2022-02-10 Emerald Health Pharmaceuticals Inc Cannabigerol quinone acid and salts thereof
US20220184003A1 (en) * 2019-02-06 2022-06-16 Emerald Health Pharmaceuticals Inc Formulations of Cannabidiol Derivatives and Their Use as Modulators of Cannabinoid Receptor Type 2 (CB2)
EP3937925A1 (en) 2019-03-12 2022-01-19 EPM (IP), Inc. Cannabinoid acid ester compositions and uses thereof
US20220347096A1 (en) 2019-10-03 2022-11-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Liposomal cannabinoids and uses thereof
WO2021139741A1 (zh) * 2020-01-08 2021-07-15 成都百裕制药股份有限公司 大麻二酚衍生物及其制备方法和在医药上的应用
EP4089081B1 (en) 2020-01-08 2025-07-23 Chengdu Baiyu Pharmaceutical Co., Ltd. Tetrahydrocannabinol derivative, and preparation method therefor and medical use thereof
EP4099993A4 (en) * 2020-02-06 2024-03-13 Emerald Health Pharmaceuticals Inc. COMPOSITION AND METHOD FOR TREATING AND PREVENTING CARDIAC, LUNG, SKIN AND KIDNEY FIBROSIS
IL303739A (en) * 2020-12-24 2023-08-01 Buzzelet Development And Technologies Ltd Compositions including cannabinoid esters
CN114315585B (zh) * 2022-03-04 2022-05-13 中国医学科学院药用植物研究所 一种羟戊苯甲酸双酯化合物及其制备方法和制药应用
CN116407529B (zh) * 2023-03-24 2024-05-10 南京医科大学 3-硝基-2,6-二羟基苯甲酸右崁醇或葑醇的酯的药物用途
WO2025168780A1 (en) 2024-02-09 2025-08-14 Universidad de Córdoba Cannabinoid aminoquinone compounds as activators of ampk/sirtuin-1 pathway

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159892A0 (en) * 2004-01-15 2004-06-20 Yissum Res Dev Co Use of quinonoid derivatives of cannabinoids in the treatment of malignancies
US20090093521A1 (en) * 2005-06-14 2009-04-09 Maria Laura Bolognesi 2, 5-Bis-Diamine [1,4] Benzoquinone-Derivatives
JP2010520269A (ja) * 2007-03-05 2010-06-10 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム カンナビノイドの新規キノノイド誘導体及び悪性腫瘍の治療におけるそれらの使用
US8772349B2 (en) * 2010-03-26 2014-07-08 Vivacell Biotechnology Espana, S.L. Cannabinoid quinone derivatives
WO2012012498A2 (en) * 2010-07-20 2012-01-26 Pulmatrix, Inc. Use of trp channel agonists to treat infections

Also Published As

Publication number Publication date
US20170044092A1 (en) 2017-02-16
CN106232570B (zh) 2018-08-07
BR112016023902A2 (pt) 2017-08-15
KR20160146765A (ko) 2016-12-21
AU2014390738B2 (en) 2019-05-02
IL248030B (en) 2019-10-31
WO2015158381A1 (en) 2015-10-22
ES2692693T3 (es) 2018-12-04
DK3131874T3 (en) 2018-11-19
CN106232570A (zh) 2016-12-14
AU2014390738A1 (en) 2016-10-27
IL248030A0 (en) 2016-11-30
KR102256398B1 (ko) 2021-05-27
CA2945867A1 (en) 2015-10-22
JP6167248B2 (ja) 2017-07-19
EP3131874A1 (en) 2017-02-22
RU2016137668A (ru) 2018-05-16
RU2667504C2 (ru) 2018-09-21
MX352386B (es) 2017-11-22
JP2017516753A (ja) 2017-06-22
RU2016137668A3 (es) 2018-05-16
CA2945867C (en) 2021-11-09
EP3131874B1 (en) 2018-07-25
US9701618B2 (en) 2017-07-11

Similar Documents

Publication Publication Date Title
MX352386B (es) Nuevos derivados quinona de cannabidiol.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX380122B (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
MD20140112A2 (ro) Analogi carba-nucleozidici 2'-substituiţi pentru tratamentul antiviral
MX377552B (es) Proceso para preparar un compuesto antiviral de formula i.
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
PH12018500268A1 (en) 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
TW201613909A (en) Benzoxazinone amides as mineralocorticoid receptor modulators
PH12016501462A1 (en) Neprilysin inhibitors
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
PH12017500737B1 (en) Kcnq2-5 channel activator
PH12018501621A1 (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
BR112017000584A2 (pt) inibidores da aldosterona sintase
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
MX358084B (es) Nuevos derivados de cannabigerol.

Legal Events

Date Code Title Description
FG Grant or registration